Dynamics and evolution of HIV-1 during structured treatment interruptions

AIDS Reviews

Volumn 4, Issue 3, 2002, Pages 119-127

  Frost, Simon D W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dynamics; Evolution; HAART; HIV; Mathematical models; Structured therapy interruption (STI)

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

CLINICAL TRIAL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MATHEMATICAL MODEL; NONHUMAN; REBOUND; REVIEW; RISK BENEFIT ANALYSIS; STOCHASTIC MODEL; TOXICITY TESTING; VIROGENESIS; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; VIRAL LOAD;

EID: 0036629953     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Perelson A. Modeling viral and immune system dynamics. Nat Rev Immunol 2002;2:28-36.
2. Perelson A, Neumann A, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;27:1582-6.
3. Arnaout R. Nowak M, Wodarz D. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Roy Soc Lond B 2000;267:1347-54.
4. Grossman Z, Polis M. Feinberg M, et al. Ongoing HIV dissemination during HAART. Nat Med 1999;5:1099-104.
5. Ribeiro R. Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci USA 2000;97:7681-6.
6. McLean A. Nowak M. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992;6:71-9.
7. Frost SDW, McLean A. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994;8:323-32.
8. Frost SDW. Nijhuis M, Schuurman R, et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1 infected individuals: the relative roles of drift and selection. J Virol 2000;74:6262-8.
9. Dybul M, Chun T, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-6.
10. Rosenberg E, Altfeld M, Poon S, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
11. Oxenius A, Price DA, Easterbrook P, et al. Early highly active antiretroviral therapy for acute HIV infection preserves immune function of CD8+ and CD4+ lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7.
12. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:29-40.
13. Ruiz L, Carcelain G, Martínez-Picado J, et al.. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:19-27.
14. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1 infected subjects. Proc Natl Acad Sci USA 2001;98:13288-93.
15. Hirschel B, Fagard C, Oxenius A, et al. SSITT: a prospective trial of treatment interruptions in HIV infection. 9th CROI. Seattle, USA. February 2002 [abstract 528].
16. Deeks SG, Wrin T, Liegler T, et al. Virological and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
17. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67.
18. Altfeld M, Walker B. Less is more? STI in acute and chronic HIV-1 infection. Nat Med 2001;7:881-4.
19. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 2001;2981-7.
20. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001;14:29-37.
21. Gulick R. Structured treatment interruption in patients infected with HIV - a new approach to therapy? Drugs 2002;62:245-53.
22. Havlier D. Structured intermittent treatment for HIV disease: necessary concession or premature compromise? Proc Natl Acad Sci USA 2002;99:4-6.
23. Hogg RS, Havlir D, Miller V, et al. To stop or not to stop: That is the question, but what is the answer? AIDS 2002;16:787-9.
24. Ruis L, Martínez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000;14:397-403.
25. Frost SDW, Martínez-Picado J, Ruiz L, et al. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 2002;76:968-79.
26. Oxenius A, McLean A, Fischer M, et al. Viral and HIV-specific CTL dynamics during intermittent antiretroviral therapy in chronically HIV-infected patients. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. February 2002 [abstract 495].
27. Haase AT. Transmission and propagation of SIV and HIV infection in vivo. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. February 2002 [abstract L9].
28. Ogg G, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
29. Altfeld M, Van Lunzen J, Frahm N. et al. Expansion of pre-existing lymph node-localized CD8+ T-cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest 2002;109:837-43.
30. Lloyd A. The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proc Roy Soc Lond B 2001;268:847-54.
31. Nowak M, Bangham C. Population dynamics of immune responses to persistent viruses. Science 1996;272:74-9.
32. Nowak M, Lloyd A, Vásquez G, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997;71:7518-25.
33. Martínez-Picado J, Frost SDW, Marfil S, et al. Viral populations emerging in plasma during sequential structured treatment interruptions in chronically HIV-infected individuals are genetically distinct between time-points and tissues. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. February 2002 [abstract 50].
34. Bonhoeffer S, Rembiszewski M, Ortiz G, et al. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 2000;14:2313-22.
35. Dorman KS, Kaplan AH, Lange K, et al. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J Acquir Immun Def Synd 2000;25:398-402.
36. Martínez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002;16:895-9.
37. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC resistant HIV-1 variants in primary cells due to a processitivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-9.
38. Perrin L, Yerly S, et al. Selection of the 184V/I mutations during strategic treatment interruption (Swiss Spanish Intermittent Treatment Trial - SSITT). Antiviral Therapy 2002;7:59.
39. Folt A, Paolucci S, Maseratt R, et al. No selection of HIV-1 resistant strains after eight cycles of structured treatment interruption in a controlled, randomized clinical trial (RIGHT 901). Antiviral Therapy 2002;7:51.
40. Mellors J, Rinalfo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
41. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340:1683-40.
42. Wodarz D, Nowak MA. Specific therapy regimes could lead to long-term immunological control of HIV. Proc Natl Acad Sci USA 1999;96:14464-9.
43. Wodarz D, Arnaout R, Nowak M, et al. Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. Phil Trans Roy Soc B 2000;355:1021-9.
44. Wodarz D, Jansen VAA. The role of T-cell help for anti-viral CTL responses. J Theor Biol 2001;211:419-32.
45. Wodarz D. Helper-dependent vs helper independent CTL responses in HIV infection: Implications for drug therapy and resistance. J Theor Biol 2001;213:447-59.
46. Adams B, Holte S, Randolph T, Banks HT. STI control of HIV infection. 1st SIAM Conference on the Life Sciences. Boston, USA. March 2002.
47. Joshi HR. Optimal control of an HIV immunology model. 1st SIAM Conference on the Life Sciences. Boston, USA. March 2002.
48. Wein LM, Zenois SA, Nowak MA. Dynamic multi-drug therapies for HIV: A control theoretic approach. J Theor Biol 1997;185:15-29.
49. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998;192:81-98.
50. D'Amato RM, D'Aquila RT, Wein LM. Management of antiretroviral therapy: modeling when to change therapy. Antivir Ther 1998;3:147-58.
51. Álvarez-Ramirez J, Meraz M, Velasco-Hernández JX. Feed-back control of the chemotherapy of HIV. Int J Bifurc Chaos 2000;10:2207-19.
52. Maree AFM, Keulen W, Boucher CAB et al. Estimating relative fitness in viral competition experiments. J Virol 2000;74:11067-72.
53. Bonhoeffer S, De Boer R. Procedures for reliable estimation of viral fitness from time series data. 9th International Workshop on HIV Dynamics and Evolution. Lake Arrowhead, CA, USA. March 2002.
54. Adcock R. Note on the method of least squares. The Analyst 1877;4:183-4.